Glecaprevir-Pibrentasvir Mavyret
Ledipasvir-Sofosbuvir Harvoni
Ribavirin Copegus, Rebetol, Ribasphere
Sofosbuvir Sovaldi
Sofosbuvir-Velpatasvir Epclusa
Sofosbuvir-Velpatasvir-Voxilaprevir Vosevi
Peginterferon alfa-2a Pegasys
Peginterferon alfa-2b PegIntronCommon TitleC-WORTHY Coinfection
Official Title Efficacy and Safety of 8 weeks versus 12 weeks of Treatment with Grazoprevir (MK-5172) and Elbasvir (MK-8742) with or without Ribavirin in Patients with Hepatitis C virus Genotype 1 Mono-Infection and HIV/hepatitis C virus Co-Infection (C-WORTHY): a Randomised, Open-Label Phase 2 Trial.
Phase Phase II
ClinicalTrials.gov NCT01717326
Treatments
Elbasvir-Grazoprevir
Elbasvir-Grazoprevir
Tradename:ZepatierOther Names:EBR-GZRClass:FDA-ApprovedFunding
IndustryMerck Sharp & Dohme Corp.